Biontech
BioNTech SE, headquartered in Mainz, Germany, is a pioneering biotechnology company renowned for its innovative approach to immunotherapy. Founded in 2008, BioNTech has rapidly established itself as a leader in the development of personalised cancer treatments and infectious disease vaccines, notably its groundbreaking mRNA technology. The company gained global recognition for its collaboration with Pfizer in creating one of the first COVID-19 vaccines, marking a significant milestone in the fight against the pandemic. BioNTech's core offerings include mRNA-based therapeutics and vaccines, which are distinguished by their ability to elicit robust immune responses. With a strong market position and a commitment to advancing medical science, BioNTech continues to push the boundaries of biotechnology, aiming to transform patient care worldwide.
DitchCarbon Score
How does Biontech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biontech's score of 33 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biontech's reported carbon emissions
In 2023, BioNTech reported total greenhouse gas emissions of approximately 534,182,000 kg CO2e. This figure includes 1,342,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 3,339,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity, steam, heating, and cooling. The company also recorded Scope 3 emissions of about 529,501,000 kg CO2e, which cover all other indirect emissions in the value chain. BioNTech has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the baseline year. Additionally, the company plans for 72% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by 2027. These targets align with the global goal of limiting temperature rise to 1.5°C, demonstrating BioNTech's commitment to sustainability and climate action within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 607,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 2 | 2,748,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 2,445,000 | 0,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biontech is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
